A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections

NCT07232004 · tracked via the Priya Life Science USA tracker

Sponsor

AbbVie

Phase

Phase 1

Started

2025-11-24

Last updated

2026-07-24

Condition(s) studied

Healthy Volunteer

Investigational drug(s) / intervention(s)

ABBV-547ABBV-547 Placebo

ABBV-547: Parental Administration

ABBV-547 Placebo: Parental Administration

Study summary

The purpose of this study is to assess how safe, effective, and tolerable ABBV-547 is in adult participants in the United States and Japan.

There will be 2 parts to this study. In Part 1, participants are placed in one of 7 groups where they will receive ABBV-547 at different doses or placebo. There is a 1 in 4 chance participants will receive placebo. In Part 2, participants are placed in one of 3 groups where they will receive ABBV-547 at different doses or placebo. There is a 1 in 7 chance participants will receive placebo. Approximately 121 adult participants will be enrolled at approximately 21 sites in the United States and Japan.

Participants will be administered one dose of ABBV-547 or placebo.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Eligibility

Sex

ALL

Min age

18 Years

Max age

55 Years

Healthy volunteers

Accepted

Inclusion Criteria: * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG). * Part 1: BMI is \>= 18.0 to \<= 29.9 kg/m\^2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters. * Part 2: must have discontinued use of phototherapy (e.g., UVA or UVB) at least 2 weeks prior to the baseline visit (Day 1) and PUVA phototherapy at least 4 weeks prior to the baseline visit (Day 1). Exclusion Criteria: * History of any clinically significant sensitivity or allergy to any medication or food. * Part 2: uses any herbal supplements within the 2-week period prior to study treatment administration. * Part 2: received any biologics including investigational agents within 2.5 half-lives prior to Baseline.

Primary outcome measure(s)

Number of Participants with Adverse Events (AEs) — Up to Approximately Day 365
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Trial sites (23)

Facility	City	Region
Total Dermatology /ID# 279798	Birmingham	Alabama
Dermatology Trial Associates /ID# 279984	Bryant	Arkansas
CenExel ACT- Anaheim Clinical Trials /ID# 279612	Anaheim	California
Dermatology Research Associates - Los Angeles /ID# 279383	Los Angeles	California
Integrative Skin Science and Research - Location 2 /ID# 279386	Sacramento	California
Skin Care Research Boca Raton /ID# 279988	Boca Raton	Florida
Wellness Clinical Research - Miami Lakes /ID# 279803	Miami Lakes	Florida
Advanced Clinical Research Institute - Tampa /ID# 279342	Tampa	Florida
Trueblue Clinical Research - Tampa /ID# 281757	Tampa	Florida
University Dermatology & Vein Clinic - Darien /ID# 279986	Darien	Illinois
Acpru /Id# 278638	Grayslake	Illinois
MetroBoston Clinical Partners /ID# 279992	Boston	Massachusetts
Minnesota Clinical Study Center /ID# 279987	New Brighton	Minnesota
MediSearch Clinical Trials /ID# 279416	Saint Joseph	Missouri
Skin Specialists /ID# 279531	Omaha	Nebraska
The Skin Center Dermatology Group /ID# 279983	New City	New York
Equity Medical, LLC - Bronx /ID# 279808	The Bronx	New York
Oregon Dermatology and Research Center /ID# 279391	Portland	Oregon
Health Concepts /ID# 279529	Rapid City	South Dakota
Center for Clinical Studies - Houston - Binz Street /ID# 279419	Houston	Texas
Austin Institute for Clinical Research - Pflugerville /ID# 279387	Pflugerville	Texas
University of the Ryukyus Hospital /ID# 279918	Ginowan-shi	Okinawa
Fukuoka University Hospital /ID# 279530	Fukuoka	Japan

More AbbVie trials in the USA

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) Recruiting

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer Active, not recruiting

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) Active, not recruiting

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) Active, not recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma Active, not recruiting

Other trials for the same condition

A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants Recruiting

Healthy Volunteer Study Active, not recruiting

A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old Recruiting

Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy Volunteers Starting soon

A Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy Participants Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07232004 on ClinicalTrials.gov ↗ ← All trials in the USA